AI analysis for enhanced 3D screening assay data capture

Image-based high-content screening (HCS) is an effective drug discovery approach that measures cellular changes to assess medication effects.

Image Credit: Molecular Devices

Image Credit: Molecular Devices

With the increased interest in 3D biological models, researchers need an imaging platform that can provide high-throughput, high-quality imaging and advanced analytics.

This scientific poster presents the most recent addition to Molecular Devices UK Ltd.’s high-content imaging portfolio: the ImageXpress® HCS.ai High-Content Screening System. This system combines AI-driven software, modular hardware, and cutting-edge optics to improve speed, precision, and flexibility.

The poster uses 3D models to demonstrate the HCS.ai system’s capabilities, extracting multiparametric data and improving analysis accuracy through deep-learning segmentation.

The HCS.ai system accelerates research and provides deeper insights into drug discovery by combining high-throughput acquisition, deep tissue imaging, and AI-powered insights.

Download the Poster

About Molecular Devices UK Ltd

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 18, 2026 at 2:04 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Molecular Devices UK Ltd. (2026, June 18). AI analysis for enhanced 3D screening assay data capture. News-Medical. Retrieved on June 23, 2026 from https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx.

  • MLA

    Molecular Devices UK Ltd. "AI analysis for enhanced 3D screening assay data capture". News-Medical. 23 June 2026. <https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx>.

  • Chicago

    Molecular Devices UK Ltd. "AI analysis for enhanced 3D screening assay data capture". News-Medical. https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx. (accessed June 23, 2026).

  • Harvard

    Molecular Devices UK Ltd. 2026. AI analysis for enhanced 3D screening assay data capture. News-Medical, viewed 23 June 2026, https://www.news-medical.net/whitepaper/20250604/AI-analysis-for-enhanced-3D-screening-assay-data-capture.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.